Amino Acid Transporters in Cancer and Their Relevance to “Glutamine Addiction”: Novel Targets for the Design of a New Class of Anticancer Drugs
Top Cited Papers
- 30 April 2015
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 75 (9) , 1782-1788
Abstract
Tumor cells have an increased demand for amino acids because of their rapid proliferation rate. In addition to their need in protein synthesis, several amino acids have other roles in supporting cancer growth. There are approximately two-dozen amino acid transporters in humans, and tumor cells must upregulate one or more of these transporters to satisfy their demand for amino acids. If the transporters that specifically serve this purpose in tumor cells are identified, they can be targeted for the development of a brand new class of anticancer drugs; the logical basis of such a strategy would be to starve the tumor cells of an important class of nutrients. To date, four amino acid transporters have been found to be expressed at high levels in cancer: SLC1A5, SLC7A5, SLC7A11, and SLC6A14. Their induction occurs in a cancer type–specific manner with a direct or indirect involvement of the oncogene c-Myc. Further, these transporters are functionally coupled, thus maximizing their ability to promote cancer growth and chemoresistance. Progress has been made in preclinical studies, exploiting these transporters as drug targets in cancer therapy. These transporters also show promise in development of new tumor-imaging probes and in tumor-specific delivery of appropriately designed chemotherapeutic agents. Cancer Res; 75(9); 1–7. ©2015 AACR.Keywords
This publication has 55 references indexed in Scilit:
- Serine, glycine and one-carbon units: cancer metabolism in full circleNature Reviews Cancer, 2013
- Ets-1 regulates intracellular glutathione levels: key target for resistant ovarian cancerMolecular Cancer, 2013
- SLC6A14 (ATB0,+) Protein, a Highly Concentrative and Broad Specific Amino Acid Transporter, Is a Novel and Effective Drug Target for Treatment of Estrogen Receptor-positive Breast CancerJournal of Biological Chemistry, 2011
- Glutamine addiction: a new therapeutic target in cancerTrends in Biochemical Sciences, 2010
- xCT deficiency accelerates chemically induced tumorigenesisProceedings of the National Academy of Sciences, 2010
- Rethinking the Warburg Effect with Myc Micromanaging Glutamine MetabolismCancer Research, 2010
- c-Myc suppression of miR-23a/b enhances mitochondrial glutaminase expression and glutamine metabolismNature, 2009
- Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addictionProceedings of the National Academy of Sciences of the United States of America, 2008
- The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistanceBritish Journal of Cancer, 2008
- Autocrine Glutamate Signaling Promotes Glioma Cell InvasionCancer Research, 2007